Nanodecal develops rapid tests to guide therapeutical decisions in respiratory medicine. Our first product detects a respiratory superbug that threatens 400 million people with a chronic infection. Our patented solution detects the superbug within minutes, anywhere. This enables personalized antibiotic treatment, eradicating the infection before it becomes permanent. We are currently seeking investment to finish the manufacturing certification process so that we can start clinical validation studies by the end of 2024.